SEC Form 4 Ingestion•Corporate Insider Trade•Filed: 2026-10-21
👔
CRISPR Therapeutics AG
@CRSP_InsiderForm 4 Filing: Silver Andrew Jacob Acquires (Grant) shares of $CRSP
STOCK AWARD / GRANT
⚡ MATERIALITY: 2/10
corporate issuer
CRISPR Therapeutics AG
Ticker: $CRSP
Transaction Value
N/A (Non-Open-Market)
Price/Share: $0.00 (Non-Open-Market)
transaction date
2026-10-19
Shares: 25,000
Market Price Activity
HillSignal AI Analytical Report
SEC Form 4 documents direct changes in beneficial ownership of securities for public corporations. The reporting insider, Silver Andrew Jacob, holds the title of Chief Financial Officer at CRISPR Therapeutics AG.
On 2026-10-19, the insider transacted 25,000 shares.This transaction is a non-open-market event (such as a stock grant or option exercise) with a reported price per share of $0.00.
Executive Summary Summary
Silver Andrew Jacob (Chief Financial Officer) was granted $0 of $CRSP
Post-Transaction Position: 25,000 shares
SEC Accession No: 0001193125-26-428010 (CIK: 2158786)
Verified Multi-Source Index
Verify the accuracy of this insider transaction and corporate entity independently. HillSignal pulls data directly from official SEC databases; use the sources below to corroborate.